

Expert Teams – Transitions of Care

Case-Based Learning & Mentorship

Friday, February 18, 2022

Facilitator: Kelly M. Mayo, ESRD National Coordinating Center



Meeting Logistics

- Call is being recorded and will be posted to www.esrdncc.org
- Lines will be open for all high performing organizations
 - Please stay on mute unless you are speaking
 - Do not place the call on “hold”
- Everyone is encouraged to use the video and chat features



Meeting Guidelines



INTRODUCE YOURSELF
BEFORE SPEAKING



KEEP PATIENT-SPECIFIC
INFORMATION
CONFIDENTIAL



BE WILLING TO SHARE
SUCCESSSES AND
DIFFICULTIES



BE OPEN TO FEEDBACK



ASK THE DIFFICULT
QUESTIONS



RESPECT OTHERS



USE "...AND" STATEMENTS



KEEP TO TIME LIMITS

Introductions

- Meeting Focus – Transitions of Care
- Guest Expert – National Forum of ESRD Networks
 - David Henner, DO, Berkshire Medical Center (MA)
- Case Study Presenters – Kidney Patient Advisory Committee (KPAC)
 - Dawn Edwards, Patient Subject Matter Expert (NY)
 - Derek Forfang, Patient Subject Matter Expert (CA)
- High Performing Organizations
- ESRD Networks
- Centers for Medicare & Medicaid Services (CMS)



Questions to Run On

How Might We ...

- Provide patients the knowledge and skills to prevent unplanned hospitalizations?
- Address health conditions that may contribute to hospitalizations, such as anemia or undiagnosed mental health?
- Assist patients with unstable support systems or financial issues that may impact hospitalizations?

Presentation by Guest Expert

David Henner, DO

President, National Forum of ESRD Networks

Division Chief of Nephrology

Medical Director of Dialysis

Berkshire Medical Center (MA)



Forum of ESRD Networks Transitions of Care Toolkit

David E. Henner, DO

Division Chief of Nephrology

Medical Director of Dialysis

Berkshire Medical Center, Pittsfield, MA

President- Forum of ESRD Networks

What is the Forum?




All ESRD Networks are members of the Forum of ESRD Networks, which is a not-for-profit organization that advocates on behalf of its membership and coordinates projects and activities of mutual interest to ESRD Networks. The Forum facilitates the flow of information and advances a national quality agenda with CMS and other renal organizations.

The **Mission** of the Forum is to support and advocate on behalf of the ESRD Networks in promoting methods to improve the quality of care to patients with renal disease.

Core values: volunteerism, collaboration, innovation and flexibility, spread of knowledge, integrity, autonomy of individual ESRD Networks, Person (Patient & Family) Centeredness

December 2019





- Assisting the Networks
- Council Activities: MAC, EDAC KPAC
- Regular Communication with CMS
- Webinars & Toolkits
- Facilitate flow of information between the Forum and Network Staff/BOD/MRB/PAC
- Relationships with other Stakeholders (i.e. RHA, RPA, LDOs, NKF, AAKP, AHQA, CDC, ASN)

Forum Board of Directors

(Effective 07/01/2021)



Executive Committee:

President: David Henner, DO

President-Elect: Kam Kalantar-Zadeh, MD, MPH, PhD

Past President: Ralph Atkinson III, MD

Treasurer: Stephanie Hutchinson, MBA

Secretary: Chris Brown

MAC Chair: Kam Kalantar-Zadeh, MD, MPH, PhD

EDAC Chair: Brandy Vinson

EDAC Vice-Chair: Vicky Cash

KPAC Co-Chair: Derek Forfang

KPAC Co-Chair: Dawn Edwards

Members-at-Large:

Christine Logar, MD, FASN

Preethi Yerram, MD, MS, FASN

Kelly M. Mayo, MS

Keith Norris, MD PhD

Stephen Pastan, MD

Katrina Russell, RN, CNN

Ad-Hoc:

Andrew Howard, MD, FACP

Donald Molony, MD

John Wagner, MD, MBA

Emeritus:

Louis Diamond, MB, ChB, FACP, FCP (SA)



Forum of ESRD Networks Website

- <https://esrdnetworks.org/>

Are you a pa
Do you have a concern
or grievance?

Donate

The National Forum of ESRD Networks, Inc. is a registered 501(c)(3) non-profit organization #13-3246354. Your donation is tax deductible to the extent allowable by law. No goods or services will be provided by the Forum in return or consideration for this contribution. Donations can also be mailed to the

Transitions of Care Toolkit

This Toolkit for health providers and practitioners is a reference tool that gives information about challenges in transitions of care and suggestions to help create solutions.

Updated 04/12/2019: Updates to this Toolkit include guidance for nephrologists in caring for transient dialysis patients. See pages 99-100 for an explanation of the new Medication Conversion Guide and a sample Transient Dialysis Patient Form you can customize for your facility. These new tools were developed, in part, as a response to concerns expressed by kidney patients serving on the Forum's Board of Directors and Kidney Patient Advisory Council.

[Transitions of Care Toolkit - \[Updated April 2019\]](#)

[Sample Transient Dialysis Patient Form v2.0 Excel - \[03/12/2021\]](#)

[Sample Transient Dialysis Patient Form v2.0 PDF - \[03/12/2021\]](#)

[Medication Conversion Guide V1.2 - \[02/11/2019\]](#)

Video & Slides: Updates to the Transitions of Care Toolkit [Nov 2019]

Included in the April 2019 updates are 2 new tools: the Medication Conversion Guide and a sample Transient Dialysis Patient Form. Learn about these updates and tools through this short video presentation by our Forum President, Ralph Atkinson, MD and MAC Chair, David Henner, DO.

[Slides: Updates to the Transitions of Care Toolkit](#)

[Video: Updates to the Transitions of Care Toolkit](#)

Table of Contents

CHAPTER 1. INTRODUCTION AND GUIDE TO USING THIS TOOLKIT	
How to Use the Toolkit	6
Definitions and Abbreviations	7
CHAPTER 2. WHY DO WE NEED A "TRANSITIONS OF CARE" TOOLKIT?	
Why do we have a Toolkit?	10
What is unique about kidney patients?	10
What do we need to do to have good transitions?	12
How do transitions of care affect providers?	12
CHAPTER 3. WHO SHOULD USE THIS TOOLKIT AND WHO IS IT ABOUT?	
Who is the Dialysis Care Team?	14
Who are the "Customers"?	14
Why is Patient-centered Care Important for Transitions of Care?	17
CHAPTER 4. SURVEYS OF PATIENTS, PROVIDERS, AND PRACTITIONERS ABOUT TRANSITIONS OF CARE	
Surveys of Patients, Providers, and Practitioners about Transitions of Care	19
Results	19
CHAPTER 5. THE TRANSITION TO DIALYSIS: THE FIRST DIALYSIS TREATMENTS	
Part 1: Introduction	21
Part 2: Get Started	21
CHAPTER 6. DIALYSIS STAFF CHANGES	
Part 1: Introduction	28
Part 2: Get Started	28
CHAPTER 7. MODALITY CHANGES	
Part 1: Introduction	36
Part 2: Get started	37
CHAPTER 8. TRANSITIONS BETWEEN SETTINGS	
Part 1: Introduction	48
Part 2: Get started	49
CHAPTER 9. HEALTHCARE TRANSITION FROM PEDIATRIC- TO ADULT-FOCUSED DIALYSIS SERVICES	
Part 1: Introduction	65
Part 2: Get started	68
CHAPTER 10. PROBLEM SOLVING PROCESSES	
Process 1	75
Process 2	77
APPENDIX	
Online Resources for Professionals	80

2019

Transitions of Care Toolkit

Developed by the Forum of ESRD Networks' Medical Advisory Council (MAC)

This toolkit for health providers and practitioners is a reference tool that gives information about challenges in transitions of care and suggestions to help create solutions.

Tell us what you think!

Please take a moment to complete a short questionnaire about this Toolkit. We appreciate your insight and suggestions to make our resources better.

<https://www.surveymonkey.com/r/ForumResEval>

Forum Medical Advisory Council (MAC)
The Forum of ESRD Networks
First Publication: 12/01/2015
Revised: 01/09/2017
Revised, Transient Templates: 04/12/2019
© Copyright, Forum of ESRD Networks, 2019

THE NATIONAL
FORUM
OF ESRD NETWORKS

Take Home Messages:

1. “Transitions of care” are not just about discharges from a hospital. Kidney patients and their families have many unique transitions—including a massive shift in what they expect for their futures.
2. Kidney failure does not go away, though its treatment may change. Both patients and providers must be ready for change, including different renal replacement therapy options.
3. Changes that seem routine for provider staff may be highly stressful for patients. Acknowledge and discuss the patient’s fears with him or her. Do not minimize fear.
4. Communication is critical. Using easy to understand terms will reach the majority of the patients regardless of literacy or health literacy levels.
5. Respect is essential.
6. This is a complicated life journey. Many people interact with the patient. Clear, coordinated communication is key to success.

Help Engage Patients in Their Care:


1. Offer HOPE that patients can have a life that is worth living, even with their health problems. Share stories of other patients or find “buddies” to help them see that their lives are not over.
2. Seek out what motivates them so you can help them to achieve their life goals (e.g., being there for children or grandchildren, more education, pets?).
3. Show respect.
4. Support autonomy (self-directed choices).
5. Educate them to feel competent and equip them to take on self-management tasks, such as following a meal plan or taking medicines the right way.

Why are many transitions difficult for patients?


- Lack of understanding of the treatment plan
- Not being included in making the plan or goals in the first place
- Being overwhelmed and dazed
- Anger and/or depression
- Lack of resources (e.g., transportation)
- Discomfort and pain
- Getting conflicting advice from others
- Distrust of providers
- Other issues, such as work schedule or family needs
- Denial that the illness is even present
- Fear of the unknown—or even of the known—effects of following the treatment plan

Helping patients with transitions:

1. Speak with the patient about his or her values. What matters most?
 - Each person has different priorities. Here are a few:
 - A long life
 - A better quality of life
 - Spending more time with loved ones
 - Keeping a job
 - Having a child
2. Frame your communications in terms of how the desired behavior will help support the patient's values and goals.
 - For example, a patient who wants to keep his job may be motivated to choose a home dialysis option for schedule flexibility.

What Patients Say	Causes	Solutions
 <p data-bbox="170 405 475 719">"I had a hard time transitioning into dialysis and being properly informed about treatment options available."</p>	<p data-bbox="595 189 1058 272">2. Not knowing treatment options</p> <ul data-bbox="595 289 1074 805" style="list-style-type: none"> <li data-bbox="595 289 1074 515">• Education about treatment options may not have been done or may have been done at a difficult time. <li data-bbox="595 532 1074 662">• The patient was too overwhelmed to understand the options. <li data-bbox="595 679 1074 805">• Options may have been presented in a biased manner. 	<ul data-bbox="1112 189 1808 1298" style="list-style-type: none"> <li data-bbox="1112 189 1808 468">• Even if it was done pre-dialysis, repeat dialysis options education (if appropriate). Do not present modality options in terms of "pros or cons," since what is a "pro" for one patient may be a "con" for another. <li data-bbox="1112 485 1808 763">• Have a patient who is on a different modality speak with the patient about that modality. A patient who has used more than one modality may be very helpful. Patients often listen more to each other than they do to staff. <li data-bbox="1112 781 1808 911">• Provide written and online educational resources, like www.mydialysischoice.org. <li data-bbox="1112 928 1808 1058">• Stress that there are options (if appropriate) and that the patient's choices may change over time. <li data-bbox="1112 1075 1808 1298">• Discuss all modalities, <u>even those not offered by your clinic</u>. This is a regulatory requirement. There may be another clinic available to the patient that does offer that modality.

What Patients Say	Causes	Solutions
<p data-bbox="131 258 575 468">“Not knowing what I don’t know yet.”</p> <p data-bbox="131 486 575 696">“I passed out because my blood pressure fell too low.”</p> <p data-bbox="131 715 575 925">“No one explained what they were doing or why.”</p> <p data-bbox="131 943 575 1153">“There was no consideration that this was my first treatment.”</p>	<p data-bbox="614 248 1070 334">3. Not knowing what to expect</p> <ul data-bbox="614 344 1070 1196" style="list-style-type: none"> <li data-bbox="614 344 1070 476">• The patient did not visit a dialysis clinic before starting treatment. <li data-bbox="614 486 1070 619">• No one took the time to explain each step of before or during the treatment. <li data-bbox="614 629 1070 905">• The patient has language or other barriers to understanding what has been discussed. <li data-bbox="614 915 1070 1048">• The patient did not want to know anything before starting (denial?). <li data-bbox="614 1058 1070 1190">• The patient is very scared. 	<ul data-bbox="1116 248 1798 1239" style="list-style-type: none"> <li data-bbox="1116 248 1798 525">• Whenever possible, have the patient and/or family visit the clinic and meet with the nurse or other staff before starting treatment. Discuss what will happen at each step starting when the patient enters the clinic. <li data-bbox="1116 535 1798 812">• Have a nurse and/or PCT explain each step of the treatment before, during, and after. If you can, arrange for extra staffing when a new patient starts dialysis. Have a designated “trainer” or at least a standard process for staff to follow. <li data-bbox="1116 822 1798 1048">• Include family in the clinic orientation and teaching processes as much as possible, depending on the patient’s wishes. <li data-bbox="1116 1058 1798 1239">• Think about having an orientation area for new patients. You can also ask a current patient to be a buddy for a new patient—speak with him or her

What Patients Say	Causes	Solutions
 <p>"Where is my usual nurse?"</p>	<p>Why is it hard for patients to adapt to new or different staff members?</p> <p><i>(Note that the causes and possible solutions shown here do not line up. It will be your job to line up causes and solutions for your own clinic.)</i></p>	<p>What can we do now and in the future to make the transitions in staffing a better experience for patients?</p>

Author's Note: Access issues are covered first, since access cannulation is a major concern when patients were asked about staffing changes in our surveys. Pain was noted more often than loss of the access.

"New techs do not have a good understanding of my access, depth, curves, narrowing, etc., causing the new staff member to fish around the access to cannulate, causing pain and infiltration."

What Patients Say	Causes	Solutions
<p>"New techs do not have a good understanding of my access, depth, curves, narrowing, etc., causing the new staff member to fish around the access to cannulate, causing pain and infiltration."</p>	<p>1. Fear of painful cannulation or access damage by new staff</p> <ul style="list-style-type: none"> • There is no common place to share access details, which is especially vital for the patient with a difficult or unusual access. • Orientation for new staff members, especially PCTs, is often too short. • Staff may not have been thoroughly educated about how to assess an access prior to cannulation. • Senior staff do not mentor newer staff. New staff are allowed to cannulate without a 	<ul style="list-style-type: none"> • Make sure there is a section in each patient's chart (or EMR or clipboard) with a detailed access drawing if a fistula or graft is present, with information about cannulation. Require all RNs and PCTs to view the drawing before cannulating if they have not worked with the patient before. • Insist on in-depth staff education that includes access assessment and prolonged mentoring by senior staff. Do not pretend that a new staff person has extensive experience. • Make sure that there is always a PCT or RN with good cannulation skills in the clinic to help other staff who need it. Enforce policies that limit the number of cannulation attempts, and <u>tell patients</u> about those policies. • Staff floating within one company's clinics should have the same skills.

Sample Transient Dialysis Patient Form:

Developed by the Forum MAC, this form can be customized to fit your facility needs but includes some of the information felt to be most important for the receiving dialysis facility to know how to deliver the best care to the visiting patient while at the facility away from home.

<https://esrdnetworks.org/resources/toolkits/mac-toolkits-1/new-toolkit-transitions-of-care-toolkit>

Medication Conversion Guide:

Intended to assist physicians to convert the does of a medication a patient is currently receiving, to a substitute medication that is available, or less costly. Medications converted using this tool must be approved or ordered by the patient's Nephrologist, however, we encourage all care providers and patients to share this guide with their care teams.

<https://esrdnetworks.org/resources/toolkits/mac-toolkits-1>

Update to Transfer Summary Form- updated to include COVID-19 status and Vaccine

Dialysis Facility Name and Location:			
Dialysis Facility Contact Name:			
Dialysis Facility Contact Phone:		Fax:	
*****Please fill in all information			
Patient Name:		Date of Birth:	
Requested Dates:		Patient Phone:	
Referring Facility:		Referring Facility Phone:	
Referring Facility Contact Person Name:		Code Status: full code DNR Other:	
How will Patient be transported to the center:			
Is the Patient Ambulatory:	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Is the Patient Trach or Vent Dependent:	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Can Patient sit in standard chair to dialyze:	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Can Patient Sign own legal consents:	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Has pt had disruptive behavior on dialysis:	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Hospitalizations in previous 3 months?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
If yes, please provide dx: _____			
Has patient had Infection(s) in last 60 days?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
If yes, please provide dx: _____			
If pt is on antibiotic, please list name, dose and schedule: _____			
Number of missed treatments within past 2 weeks (before travel): _____			
Current Dialysis Access:	AVF	AVG	Cuffed-Tunneled Catheter
If AVF, Buttonholes?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Needle Size: 15g 16g 17g
Is patient > 2 kg above EDW at his last dialysis treatment?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Meds given on dialysis -Include dose, frequency, and date last given:			

Any Symptoms of possible COVID-19? _____
Name of patient's Primary Nephrologist to contact for any questions: _____
Phone number/pager of Primary Nephrologist to contact if any questions: _____
** Please fax copy of the following (required):
<input type="checkbox"/> Current Dialysis Prescription Orders
<input type="checkbox"/> Updated Medication List and Allergies. * **Please include medications given on dialysis**
<input type="checkbox"/> Current Month and previous month's Labs (including URR), electrolytes, Calcium, Phos, and Hgb
<input type="checkbox"/> Problem List/Comorbiditis or H+P within 1 year
<input type="checkbox"/> EKG within 1 year
<input type="checkbox"/> Hepatitis (Hep) B Surface Ag results within 1 month, Hep B S Antibody and Hep C Antibody within 1 year
<input type="checkbox"/> Demographic information
<input type="checkbox"/> Completed 2728 Form
<input type="checkbox"/> Copies of all active insurance cards (front and back)
<input type="checkbox"/> MSP Questionnaire
<input type="checkbox"/> Authorization to Treat & Financial Consent Forms
<input type="checkbox"/> Involvement of Care Form
<input type="checkbox"/> Confidentiality Form (demographic information and Privacy Practices)
<input type="checkbox"/> PPD results within 1 yr, if + PPD please send CXR results within 1 yr
<input type="checkbox"/> Patients transferring for >30 days, also need up-to-date comprehensive assessment(s) and plan of care
<input type="checkbox"/> Documentation of COVID-19 Vaccine(s) OR documentation of most recent neg COVID-19 PCR test(s)
***We may transfer transient patient to another of our facilities if chair needed for new patient start
Form updated by ESRD Forum of Networks MAC, V2.0- Lauren Schutz and David Henner, DO 3/12/2021

Medication Conversion Guide

Conversion Guide for Hemodialysis Patients Visiting Dialysis Facilities

This is a Guide to be used to help convert dose of medication patient currently on, to one that is available or less costly

**This is only a guide- any medication changes must be ordered by/approved by Nephrologist covering patient

***This guide is being used to help better serve patients on dialysis, and therefore includes both Brand Names and generic names of medications. The use of brand names is to facilitate use of the tool.

Instructions on Use:

1. Look for current medication that you wish to convert in Column B and medication you wish to convert to in Column G and chose appropriate row that includes both.
2. Enter dose of current medication in column C (shaded green), and equivalent dose of medication you wish to convert to will be listed in column H (shaded red).
3. See column L for dose forms, and round dose in column H off to closest dose that can be used, using available dose forms in column L (check dialysis facility for dosage forms available)
4. Do not exceed maximum recommended dose of medication listed in column M, without specific written or electronic order entered by Nephrologist.

Current Medication	Enter Current				Substitute Medication	Equivalent				Substitute Med Dosage Form	Maximum Recommended Dose
	Dose Here:	Units	Route	Frequency		Dose	Units ²	Route ³	Frequency ⁴		
Aranesp (Darbepoetin)		mcg	IV	Weekly	Epogen (Epoetin Alpha)	0	units	IV	q Tx	2,3, 4, 10, or 20,000 units/ml	175 units/kg
Aranesp (Darbepoetin)		mcg	IV	Weekly	Mircera (Methoxy polyethylene glycol-epoetin beta)	0	mcg	IV	q 2 Weeks	30, 50, 75, 100, 150, 200 mcg/0.3 ml	180 mcg q 2 weeks
Calcitriol		mcg	PO/IV	q Tx	Hectorol (Doxercalciferol)	0	mcg	PO	q Tx	2.5 mcg PO Capsule	20 mcg
Calcitriol		mcg	PO/IV	q Tx	Hectorol (Doxercalciferol)	0	mcg	IV	q Tx	2 mcg/ml, 4 mcg/ml IV vials	18 mcg
Calcitriol		mcg	PO/IV	q Tx	Zemplar (Paricalcitol)	0	mcg	PO/IV	q Tx	2 mcg PO caps, 2 mcg/ml IV	16 mcg
Epogen (Epoetin Alpha)		Units	IV	q Tx	Aranesp (Darbepoetin)	0	mcg	IV	Weekly	10, 25, 40, 60, 100, 200 mcg/ml	200 mcg IV Weekly
Epogen (Epoetin Alpha)		Units	IV	q Tx	Mircera (Methoxy polyethylene glycol-epoetin beta)	0	mcg	IV	q 2 Weeks	30, 50, 75, 100, 150, 200 mcg/0.3 ml	180 mcg q 2 weeks
Ferrlecit (Ferric gluconate)		mg	IV	Weekly	Venofer (Iron Sucrose)	0	mg	IV	Weekly	20 mg/ml (2.5, 5, 10 ml)	100 mg IV q tx
Ferrlecit (Ferric gluconate)		mg	IV	q Tx	Venofer (Iron Sucrose)	0	mg	IV	q Tx	20 mg/ml (2.5, 5, 10 ml)	100 mg IV q tx
Hectorol (Doxercalciferol)		mcg	IV	q Tx	Calcitriol	0.00	mcg	IV/PO	q Tx	0.25, 0.5 mcg PO, 1mcg IV	4 mcg
Hectorol (Doxercalciferol)		mcg	PO	q Tx	Calcitriol	0.00	mcg	IV/PO	q Tx	0.25, 0.5 mcg PO, 1mcg IV	4 mcg
Hectorol (Doxercalciferol)		mcg	PO	q Tx	Hectorol (Doxercalciferol)	0	mcg	IV	q Tx	2 mcg/ml, 4 mcg/ml IV vials	18 mcg
Hectorol (Doxercalciferol)		mcg	IV	q Tx	Hectorol (Doxercalciferol)	0.00	mcg	PO	q Tx	2.5 mcg PO Capsule	20 mcg
Hectorol (Doxercalciferol)		mcg	PO	q Tx	Zemplar (Paricalcitol)	0	mcg	PO/IV	q Tx	2 mcg PO caps, 2 mcg/ml IV	18 mcg
Mircera (Methoxy polyethylene glycol-epoetin beta)		mcg	IV	q 2 Weeks	Aranesp (Darbepoetin)	0	mcg	IV	Weekly	10, 25, 40, 60, 100, 200 mcg/ml	200 mcg IV Weekly
Mircera (Methoxy polyethylene glycol-epoetin beta)		mcg	IV	q 2 Weeks	Epogen (Epoetin Alpha)	0	units	IV	q Tx	2,3, 4, 10, or 20,000 units/ml	175 units/kg
Venofer (Iron Sucrose)		mg	IV	Weekly	Ferrlecit (Ferric gluconate)	0	mg	IV	Weekly	12.5 mg/ml (5 ml)	250 mg
Venofer (Iron Sucrose)		mg	IV	q Tx	Ferrlecit (Ferric gluconate)	0	mg	IV	q Tx	12.5 mg/ml (5 ml)	250 mg

Physician enters dosage of current/regular medication in the left column, conversion to alternative medication and dosage is automatically calculated in the left columns.

Current Medication	Enter Current				Substitute Medication	Equivalent				Substitute Med Dosage Form	Re
	Dose Here:	Units	Route	Frequency		Dose	Units2	Route3	Frequency4		
Aranesp (Darbepoetin)		mcg	IV	Weekly	Epogen (Epoetin Alpha)	0	units	IV	q Tx	2,3, 4, 10, or 20,000 units/ml	17
Aranesp (Darbepoetin)	60	mcg	IV	Weekly	Mircera (Methoxy polyethylene glycol-epoetin beta)	96	mcg	IV	q 2 Weeks	30, 50, 75, 100, 150, 200 mcg/0.3 ml	18
Calcitriol		mcg	PO/IV	q Tx	Hectorol (Doxercalciferol)	0	mcg	PO	q Tx	2.5 mcg PO Capsule	20
Calcitriol		mcg	PO/IV	q Tx	Hectorol (Doxercalciferol)	0	mcg	IV	q Tx	2 mcg/ml, 4 mcg/ml IV vials	18
Calcitriol		mcg	PO/IV	q Tx	Zemplar (Paricalcitol)	0	mcg	PO/IV	q Tx	2 mcg PO caps, 2 mcg/ml IV	16
Epogen (Epoetin Alpha)		Units	IV	q Tx	Aranesp (Darbepoetin)	0	mcg	IV	Weekly	10, 25, 40, 60, 100, 200 mcg/ml	20
					Mircera (Methoxy polyethylene					30 50 75 100 150 200	

Questions / Comments:

Dee LeDuc, Forum Coordinator

forumcoord@centurytel.net

Forum website: <http://esrdnetworks.org/>



<https://facebook.com/esrdnetworks>



<https://twitter.com/ESRDNetworks>

Subscribe to our YouTube channel: <https://www.youtube.com/channel/UC9Vp4Hfu7VmSTbSwG7-6e2g>

Tag us in your tweets: @ESRDNetworks

Sharing something about the KPAC? Use #KPACPatientVoice



Q&As – 5 Minutes



Case Study Presentation

Dawn Edwards

KPAC Co-Chair

Derek Forfang

KPAC Co-Chair



Q&As – 5 Minutes



Questions to Run On -- Revisited

How Might We ...

- Help patients to adjust behaviors that may contribute to hospitalizations, such as not taking medications, smoking, or missing appointments?
- Address health conditions that may contribute to hospitalizations, such as anemia or undiagnosed mental health?
- Support patients with unstable support systems or financial issues that may impact hospitalizations?

Recap & Next Steps


- Top take-aways
- Additional pathways for learning



Social Media



ESRD National Coordinating Center



@esrd_ncc



@esrdncc



ESRD NCC | End Stage Renal Disease
National Coordinating Center (NCC)



Expert Teams – Case-Based Learning & Mentorship

Thank You

Kelly M. Mayo
kmayo@hsag.com
813-865-3552

This material was prepared the End Stage Renal Disease National Coordinating Center (ESRD NCC) contractor, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents presented do not necessarily reflect CMS policy nor imply endorsement by the U.S. Government. Publication Number FL-ESRD NCC-NC1TDV-09232021-01

